<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00570479</url>
  </required_header>
  <id_info>
    <org_study_id>Texas Retina DC-02</org_study_id>
    <nct_id>NCT00570479</nct_id>
  </id_info>
  <brief_title>Prophylactic Anecortave Acetate in Patients With a Retisert Implant</brief_title>
  <official_title>Prevention of Steroid-induced Glaucoma Using Anecortave Acetate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Retina Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Texas Retina Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retisert implant is an effective therapy for controlling inflammation in patients with&#xD;
      non-infectious posterior uveitis. One of the major complications of this device is the&#xD;
      development of elevated intraocular pressure (IOP) following implantation in 60% of patients.&#xD;
      Glaucoma filtering is required in over 30% of patients at 2 years. Anecortave acetate (AA)&#xD;
      has been shown to reduce steroid induced elevated IOP. The purpose of this study was to&#xD;
      evaluate the ability of prophylactic anterior juxtascleral depot administration of AA to&#xD;
      prevent this Retisert induced elevated IOP.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Test Article: Anecortave Acetate: 6% and 10% Sterile Suspension&#xD;
&#xD;
      Drug Study Dosage: Patients will receive an injection (0.5 mL, 0.4 mL, or 0.2 mL of the 6%&#xD;
      Anecortave Acetate suspension or 0.5 mL of the 10% suspension) of study medication every 4&#xD;
      months.&#xD;
&#xD;
      Active Ingredients: Anecortave Acetate (AL-3789)&#xD;
&#xD;
      Route of Administration: Sub-Tenon injection&#xD;
&#xD;
      Objective(s): To evaluate the safety and efficacy of four dosages (50 mg, 30 mg, 24 mg, or 12&#xD;
      mg) of Anecortave Acetate (AA) for the prevention of steroid-induced intraocular pressure&#xD;
      (IOP) elevations caused by Retisert.&#xD;
&#xD;
      Study Population: Approximately 24 patients&#xD;
&#xD;
      Structure: Parallel Group Duration of Treatment: 3 years&#xD;
&#xD;
      Description: Observer-masked study of the safety and efficacy of Anecortave Acetate 6% or 10&#xD;
      % administered by a sub-Tenon injection. Up to 24 patients with recent implantation of a&#xD;
      Retisert implant will be given a sub-Tenon injection of either 0.5 mL, 0.4 mL, or 0.2 mL of&#xD;
      6% Anecortave Acetate Sterile suspension or 0.5 mL of the 10% suspension. Patients will&#xD;
      receive periodic evaluations and re-treatment every 4 months for as long as 3 years. The end&#xD;
      point will be an IOP which requires surgical intervention. An initial assessment of efficacy&#xD;
      will be made at 18 months. If any patient treated with a lower dose develops an IOP of&#xD;
      greater than 30mHg, then they are eligible to receive the 50 mg dose.&#xD;
&#xD;
      Multicenter: Yes Number of Centers: 1 Masking: Observer masked (IOP-reader)&#xD;
&#xD;
      Method of Patient Assignment:&#xD;
&#xD;
      Randomization: Yes&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients requiring glaucoma filtering surgery</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients requiring topical glaucoma medication</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Uveitis, Posterior</condition>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 mgs of anecortave acetate (0.5 ml of a 10% suspension)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 30 mgs of anecortave acetate (0.5 ml of a 6% suspension)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 24 mgs of anecortave acetate (0.4 ml of a 6% suspension)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 12 mgs of anecortave acetate (0.2 ml of a 6% suspension)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anecortave acetate</intervention_name>
    <description>Patients will receive the specified dose of anecortave acetate every 4 months in an anterior juxtascleral depot injection</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Approximately 24 patients with recent implantation of the Retisert implant who meet the&#xD;
        inclusion/exclusion criteria defined below will be enrolled in the study. They will be&#xD;
        identified from the current and future patients of the clinical practices.&#xD;
&#xD;
          -  Patients must be willing to sign an informed consent form, able to make the required&#xD;
             study visits, and able to follow instructions.&#xD;
&#xD;
          -  Patient must be at least 12 years of age.&#xD;
&#xD;
          -  Implantation of a Retisert implant in the last 12 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has history of any medical condition which would preclude scheduled study&#xD;
             visits or completion of the study (i.e., unstable cardiovascular disease)&#xD;
&#xD;
          -  Patient has insertion of a scleral buckle in the study eye.&#xD;
&#xD;
          -  Patient has known medical history of allergy or sensitivity to the steroid family of&#xD;
             drugs.&#xD;
&#xD;
          -  Patient is on anticoagulant therapy, with the exception of aspirin and antiplatelet&#xD;
             therapy. Patient has a medical history of a bleeding disorder.&#xD;
&#xD;
          -  Patient has clinical evidence of scleral thinning.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David G Callanan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Retina Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>December 9, 2007</study_first_submitted>
  <study_first_submitted_qc>December 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2007</study_first_posted>
  <last_update_submitted>June 3, 2012</last_update_submitted>
  <last_update_submitted_qc>June 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retisert</keyword>
  <keyword>Uveitis</keyword>
  <keyword>glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Uveitis, Posterior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anecortave</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

